Chow RD, Guzman CD, Wang G, et al. AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma. Nat Neurosci. 2017;20(10):1329-1341. doi:10.1038/nn.4620
Doench JG. Am I ready for CRISPR? A user’s guide to genetic screens. Nat Rev Genet. 2018;19(2):67-80. doi:10.1038/nrg.2017.97
Maass PG, Barutcu R, Weiner CL, Rinn JL. Inter-chromosomal Contact Properties in Live-Cell Imaging and in Hi-C. Mol Cell. 2018;69(6):1039-1045.e3. doi:10.1016/j.molcel.2018.02.007
Joung J, Engreitz JM, Konermann S, et al. Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood. Nature. 2017;548(7667):343-346. doi:10.1038/nature23451
Chakraborty AA, Nakamura E, Qi J, et al. HIF activation causes synthetic lethality between the tumor suppressor and the histone methyltransferase. Sci Transl Med. 2017;9(398). doi:10.1126/scitranslmed.aal5272
Giacomelli AO, Yang X, Lintner RE, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018;50(10):1381-1387. doi:10.1038/s41588-018-0204-y
Pyzocha NK, Chen S. Diverse Class 2 CRISPR-Cas Effector Proteins for Genome Engineering Applications. ACS Chem Biol. 2018;13(2):347-356. doi:10.1021/acschembio.7b00800
Chavez A, Pruitt BW, Tuttle M, et al. Precise Cas9 targeting enables genomic mutation prevention. Proc Natl Acad Sci U S A. 2018;115(14):3669-3673. doi:10.1073/pnas.1718148115
Merkle FT, Neuhausser WM, Santos D, et al. Efficient CRISPR-Cas9-mediated generation of knockin human pluripotent stem cells lacking undesired mutations at the targeted locus. Cell Rep. 2015;11(6):875-883. doi:10.1016/j.celrep.2015.04.007
Li W, Köster J, Xu H, et al. Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR. Genome Biol. 2015;16:281. doi:10.1186/s13059-015-0843-6